CompaniesIncyclix Bio

Incyclix Bio

active
Durham, NC, United States
Founded 2020
Website
About

Precision treatments that target the aberrant proliferation driving many cancers

Areas of Focus

Categories

Small Molecule PharmaceuticalNorth & South Carolina
Team (8)
Andrew Beelen
Andrew Beelen
Andrew Beelen, MDVice President of Clinical Development
Incyclix Bio
team_memberexecutive
Fred Eshelman
Fred Eshelman, Pharm.D.Chairman, Co-Founder
Incyclix Bio
team_memberfounderboard_chair
Jay Strum
Jay Strum
Jay Strum, Ph.D.Chief Scientific Officer, Co-Founder
Incyclix Bio
team_memberfounderexecutive
John Bisi
John Bisi
John Bisi, B.S.Senior Vice President of Research and Development, Co-Founder
Incyclix Bio
team_memberfounderexecutive
Karen Makhuli
Karen Makhuli
Karen MakhuliVice President, Clinical Operations
Incyclix Bio
team_memberexecutive
Max DeNies
Max DeNies, PH.D.Board Observer
Incyclix Bio
team_member
View all 8 team members →
Clinical Trials (1)
View all

Total Trials

1

As Lead Sponsor

1

As Collaborator

0

Total Enrollment

150

By Phase

PHASE1/PHASE2: 1

By Status

RECRUITING: 1
Clinical Trials Pipeline1 trial
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
2025
2026
2027
Today
NCT05735080
Hover over trial bars to see details

Recent Trials

NCT05735080Lead Sponsor
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
PHASE1/PHASE2Recruiting
150 participants
Started: Mar 28, 2023 · Completed: Jun 30, 2026
Funding History (3)
D
Aug 22, 2025
Filing
D/A
Jul 6, 2023
Filing
D
Mar 31, 2022
Filing
Locations (1)
Headquarters
Durham, NC, United States
Map

Loading map...